Treatment of tinea capitis

Annals of Pharmacotherapy

Volumn 31, Issue 3, 1997, Pages 338-348

  Abdel Rahman, Susan M ^a   Nahata, Milap C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

CLINICAL EXAMINATION; DRUG INDUCED DISEASE; HALLUCINATION; HUMAN; LIVER TOXICITY; MYCOLOGY; MYOPATHY; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; TINEA CAPITIS; TOPICAL DRUG ADMINISTRATION;

EID: 0031058591     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100313     Document Type: Review

References (134)

1. Schwanz RA, Janniger CK. Tinea capitis. Cutis 1995;55:29-33.
2. Laude TA, Shah BR, Lynfield Y. Tinea capitis in Brooklyn. Am J Dis Child 1982;136:1047-50.
3. Frieden IJ, Howard R. Tinea capitis: epidemiology, diagnosis, treatment, and control. J Am Acad Dermatol 1994;31(suppl):S42-6.
4. Prose NS. Treatment of tinea capitis. Rep Pediatr Inf Dis 1995;5:8.
5. Rosenthal JR. Pediatric fungal infections from head to toe: what's new? Curr Opin Pediatr 1994;6:435-41.
6. Williams JV, Honig PJ, McGinley KJ, Leyden JJ. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner city school children. Pediatrics 1995;96;265-7.
7. Sharma V, Hall JC, Knapp JF, Sarai S, Galloway D, Babel DE. Scalp colonization by Trichophyton tonsurans in an urban pediatric clinic. Arch Dermatol 1988;124:1511-3.
8. Bocobo FC, Eadie GA, Miedler LJ. Epidemiologic study of tinea capitis caused by T. tonsurans and M. audouinii. Public Health Rep 1965;80:891-8.
9. Terreni AA. Tinea capitis survey in Charleston, SC. Arch Dermatol 1961;83:88-91.
10. Babel DE, Baughman SA. Evaluation of the adult carrier state in juvenile tinea capitis caused by Trichophyton tonsurans. J Am Acad Dermatol 1989;21:1209-12.
11. Nyawalo JO, Bwire M. Single dose and intermittent griseofulvin regimens in the treatment of tinea capitis in Kenya. Mycoses 1988;31:229-34.
12. Abdel-Rahman SM, Nahata MC, Powell DA. Response to initial griseofulvin therapy in the pediatric patient with tinea capitis. Ann Pharmacother (in press).
13. Fitzpatrick RE, Newcomer VD. Dermatophytosis and candidiasis. In: Feign RD, Cherry JD, eds. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders Co., 1992:782-814.
14. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995;8:240-59.
15. Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd ed. Philadelphia: WB Saunders Co., 1988:186-96.
16. Bronson DM, Desai DR, Barsky S, Foley SM. An epidemic of infection with Trichophyton tonsurans revealed in a 20-year survey of fungal infections in Chicago. J Am Acad Dermatol 1983;8:322-30.
17. Prevost E. Nonfluorescent tinea capitis in Charleston, SC. JAMA 1979;242:1765-7.
18. Hebert AA. Tinea capitis. Arch Dermatol 1988;124:1554-7.
19. Hernandez AD. An approach to the diagnosis and therapy of dermatophytosis. Int J Dermatol 1980;19:540-7.
20. Bergus GR, Johnson JS. Superficial tinea infections. Am Fam Phys 1993;48:259-68.
21. Alton AV, Tunnessen WW Jr. Alopecia in children: the most common causes. Pediatr Rev 1990;12:25-30.
22. Pomeranz AJ, Fairley JA. Management errors leading to unnecessary hospitalization for kerion. Pediatrics 1994:93:986-8.
23. Elewski B. Tinea capitis: itraconazole in Trichophyton tonsurans infection. J Am Acad Dermatol 1994;31:65-7.
24. Hubbard TW, de Triquet JM. Brush culture method for diagnosing of tinea capitis. Pediatrics 1992;90:416-8.
25. Borchers SW. Moistened gauze technique to aid diagnosis of tinea capitis. J Am Acad Dermatol 1985;13:672-3.
26. Head ES, Henry JC, Macdonald EM. The cotton swab technique for the culture of dermatophyte infections - its efficacy and merit. J Am Acad Dermatol 1984;11:797-801.
27. Mackenzie DWR. Hairbrush diagnosis in detection and eradication of nonfluorescent ringworm, Br Med J 1963;2:363-5.
28. Sachs H. Theoretical limits of the evaluation of drug concentrations in hair due to irregular hair growth. Forensic Sci Int 1995;70:53-61.
29. Randall VA, Ebling FJ. Seasonal changes in human hair growth. Br J Dermatol 1991;124:146-51.
30. Howard R, Aly R, Frieden I. Analysis of Trichophyton tonsurans sensitivity to griseofulvin in vitro (abstract). Clin Res 1993;41:420A.
31. Venugopal PV, Venugopal TV. Antidermatophytic activity of garlic (Allium sativum) in vitro. Int J Dermatol 1995;34:278-9.
32. Goh CL, Tay YK, Ali KB, Koh MT, Seow CS. In vitro evaluation of griseofulvin, ketoconazole and itraconazole against various dermatophytes in Singapore. Int J Dermatol 1994;33:733-7.
33. Venugopal PV, Venugopal TV. Disk diffusion susceptibility testing of dermatophytes with allylamines. Int J Dermatol 1994;33:730-2.
34. Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol 1989;14:98-100.
35. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23:1-36.
36. Rinaldi MG. In vitro susceptibility of dermatophytes to antifungal drugs. Int J Dermatol 1993;32:502-3.
37. Macura AB. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int J Dermatol 1993;32:533-6.
38. Williams DI, Marten RH. Oral treatment of ringworm with griseofulvin. Lancet 1958;2:1212-3.
39. Becker LE. Griseofulvin. Dermatol Clin 1984;2:115-20.
40. Araujo OE, Flowers FP, King MM. Griseofulvin: a new look at an old drug. DICP Ann Pharmacother 1990;24:851-4.
41. Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981;117:16-9.
42. Jacobs PH. Treatment of fungal skin infections: state of the art. J Am Acad Dermatol 1990;23:549-51.
43. Presser SE, Blank H. Cimetidine: adjunct in treatment of tinea capitis. Lancet 1981;1:108-9.
44. Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974;53:1673-8.
45. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum comeum. Arch Dermatol 1972;106:344-8.
46. Ginsburg CM, McCraken GH Jr, Petruska M, Olsen K. Effect of feeding on bioavailability of griseofulvin in children. J Pediatr 1983;102:309-11.
47. Back DJ, Tija JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatol 1992;126(suppl 39):14-8.
48. Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal in humans. Antimicrob Agents Chemother 1982;21:151-8.
49. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
50. Bossche HV, Marichal P, LeJeune L, Coene MC, Gorrens J, Cools W. Effects of itraconazole on cytochrome P-450-dependent sterol 14a-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 1993:37:2101-5.
51. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Cauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-6.
52. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K, Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18:263-8.
53. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992;126(suppl 39):2-7.
54. Faergemann J, Zehender H, Denouel J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair, and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venerol 1993;73:305-9.
55. Juhlin L. Loss of taste and terbinafine (letter). Lancet 1992;339:1483.
56. Oskui J. Intermittent use of griseofulvin in tinea capitis. Cutis 1978;21:689-92.
57. Tanz RR, Stagl S, Esterly NB. Comparison of ketoconazole and griseofulvin for the treatment of tinea capitis in childhood: a preliminary study. Pediatr Emerg Care 1985;1:16-8.
58. Tanz RR, Hebert AA, Esterly NB. Treating tinea capitis: should ketoconazole replace griseofulvin? J Pediatr 1988;112:987-91.
59. Gan VN, Petruska M, Ginsburg CM. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J 1987;6:46-9.
60. Martinez-Roig A, Torres-Rodriguez JM, Bartlett-Coma A. Double-blind study of ketoconazole and griseofulvin in dermatophytoses. Pediatr Infect Dis J 1988;7:37-40.
61. Lopez-Gomez S, Del Palacio A, Van Custem J, Cuetara MS, Iglesias L, Rodriguez-Noriega A. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994;33:743-7.
62. Legendre R, Esola-Macre J. Itraconazole in the treatment of tinea capitis. J Am Acad Dermatol 1990;23:559-60.
63. Haroon TS, Hussain I, Mahmood A, Nagi AH, Ahmad I, Zahid M. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol 1992;126(suppl 39):47-50.
64. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995;132:98-105.
65. Alvi KH, Iqbal N, Khan KA, Haroon TS, Hussain I, Aman S, et al. A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis. In: Shuster S, Jafary MH, eds. Royal Society of Medicine Services International Congress Series No, 205, 1992:35-40.
66. Mion G, Verdon R, LeGulluche Y, Carsin H, Garcia A, Guilbaud J. Fatal toxic epidermal necrolysis after griseofulvin (letter). Lancet 1989;2:1331.
67. Taylor B, Duffill M. Toxic epidermal necrolysis from griseofulvin. J Am Acad Dermatol 1988;19:565-7.
68. Kojima T, Hasegawa T, Ishida H, Fujita M, Okamoto S. Griseofulvin induced photodermatitis. J Dermatol 1988;15:76-82.
69. Bonilla-Felix M, Verani R, Vanasse LG, Hebert A. Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy. Pediatr Nephrol 1995;9:478-9.
70. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol 1989;21:343-6.
71. Davidson BK. Myositis associated with griseofulvin therapy (letter). Am Fam Phys 1995;52:1277.
72. Lecky BRF. Griseofulvin-induced neuropathy. Lancet 1990;335:230-1.
73. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Gastroenterology 1984;86:503-13.
74. Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med 1984;144:1069-70.
75. Meiring PD, Whitelaw DA. Ketoconazole induced hepatitis. S Afr Med J 1987;72:577-8.
76. Knight TE, Shikuma CY, Knight J. Ketoconazole induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991;25:398-400.
77. Gradon JD, Sepkowitz DV. Massive hepatic enlargement with fatty change associated with ketoconazole. DICP Ann Pharmacother 1990;24:1175-6.
78. Gasior Chrzan B, Stenvold SE, Falk ES. Juvenile tinea capitis caused by Trichophyton violaceum. Hepatic reaction during ketoconazole treatment. Acta Derm Venereol 1991;71:57-8.
79. Stevens DA. Ketoconazole metamorphosis: an antimicrobial becomes an endocrine drug. Arch Intern Med 1985;145:813-5.
80. Bharija SC, Belhaj MS. Ketoconazole-induced fixed drug eruptions. Int J Dermatol 1988;27:278-9.
81. Mohamed KN. Severe photodermatitis during ketoconazole therapy (letter). Clin Exp Dermatol 1988;13:54.
82. Garty BZ, Kauli R, Livini E, Laron Z, Nitzan M. Myopathy associated with ketoconazole treatment. Am J Dis Child 1991;145:970-1.
83. Best TR, Jenkins JK, Murphy FY, Nicks SA, Bussell KL, Vesely DL. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med 1987;82:676-80.
84. Fisch RZ, Lahad A. Adverse psychiatric reactions to ketoconazole (letter). Am J Psychiatry 1989;146:939.
85. Umstead GS, Babiak LM, Tejwani S. Immune hemolytic anemia associated with ketoconazole therapy. Clin Pharm 1987;6:499-500.
86. Lavrijsen APM, Balmus KJ, Nugteren-Huying WM, Roldaan AC, van't Wout JW, Stricker BH. Hepatic injury associated with itraconazole. Lancet 1992;340:251-2.
87. Harm SK, Kim JB, Im S, Han KH, Park YK. Itraconazole-induced acute hepatitis. Br J Dermatol 1993;129:500-1.
88. Gallardo-Quesada S, Luelmo-Aguilar J, Guanyabens-Calvet C. Hepatotoxicity associated with itraconazole (letter). Int J Dermatol 1995;34:589.
89. Hay RJ. Risk benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29(suppl):S50-4.
90. Cleveland KO, Campbell JW. Hallucinations associated with itraconazole therapy (letter). Clin Infect Dis 1995:21:456.
91. Nelson MR, Smith D, Erskine D, Gazzard BG. Ventricullar fibrillation secondary to itraconazole induced hypokalemia. J Infect 1993;26:348.
92. Rosen T. Debilitating edema associated with itraconazole therapy. Arch Dermatol 1994;130:260-1.
93. Van Cauteren H, Heykants J, DeCoster R, Cauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987;9(suppl 1):S43-6.
94. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989;14:124-7.
95. Finlay AY. Global overview of Lamisil. Br J Dermatol 1994;130(suppl 43):1-3.
96. Beutler M, Hartmenn K, Kuhn M, Gartmann J. Taste disorders and terbinafine. BMJ 1993:307:26.
97. Ottervanger JP, Stricker BH. Loss of taste and terbinafine (letter). Lancet 1992;340:728.
98. Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment. Br Med J 1993;306:248.
99. Wach F, Stolz W, Hein R, Landthater M. Severe erythema anulare centrifugum-like psoriatic drug erruption induced by terbinafine. Arch Dermatol 1995;31:960-1.
100. Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. Clin Exp Dermatol 1995;20:247-8.
101. Rzany B, Mockenhaupt M, Gehring W, Schopf E. Stevens-Johnson syndrome after terbinafine therapy (letter). J Am Acad Dermatol 1994;30:509.
102. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pederson K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Ven 1994;74:391.
103. Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994;31:806.
104. Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986;20:291-3.
105. McDaniel PA, Caldroney RD. Oral contraceptives and griseofulvin interaction. Drug Intell Clin Pharm 1986;20:384.
106. Fett DL, Vukov LF. An unusual case of severe griseofulvin-alcohol interaction. Ann Emerg Med 1994;24:95-7.
107. Zimmerman M, Duruz H, Guinand O, Broccardo O, Levy P, Lacatis D, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13:1002-3.
108. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. Br Med J 1993;306:186.
109. Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993;95:445-6.
110. Package insert. Nizoral (ketoconazole). Titusville, NJ: Janssen Pharmaceutica, 1996.
111. Package insert. Sporanox (itraconazole). Titusville, NJ: Janssen Pharmaceutica, 1996.
112. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
113. Keogh A, Spratt P, McCosken C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclospohne after cardiac transplantation. N Engl J Med 1995;333:628-33.
114. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
115. Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ. Interaction of cyclosporine and itraconazole (letter). Lancet 1987;2:282.
116. Asgari M, Back DJ. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase. J Infect Dis 1995;172:1634-6.
117. Krishnaiah YS, Satanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994;37:205-7.
118. Systemic antifungal drugs. Med Lett Drug Ther 1996;38:10-2.
119. Piscitelli SC, Gross TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991;35:1765-71.
120. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509-13.
121. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, et al. Interaction of azoles with rifampin. phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
122. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavandier M, Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993;9:309-11.
123. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1984;311:1681-3.
124. Heusner JJ, Dukes GE, Rollins DE, Tolman KG, Galinsky RE. Effect of chronically administered ketoconazole on the elimination of theophylline in man. Drug Intell Clin Pharm 1987;21:514-7.
125. Magnasco AJ, Magnasco LD. Interaction of ketoconazole and ethanol. Clin Pharmacokinet 1986;5:522-3.
126. McClean KL, Sheehan GJ. Interaction between itraconazole and digoxin. Clin Infect Dis 1994;18:259-60.
127. Rex J. Itraconazole-digoxin interaction (letter). Ann Intern Med 1992;116:525.
128. Kauffman CA, Bagnasco FA. Digoxin toxicity associated with itraconazole therapy. Clin Infect Dis 1992;15:886-7.
129. Lees RS, Lees M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664-5.
130. Breckenridge A. Clinical significance of interactions with antifungal agents. Br J Dermatol 1992;126(suppl 39):19-22.
131. Cohn MS. Superficial fungal infections. Topical and oral treatment of common types. Postgrad Med J 1992;91:239-52.
132. Allen HB, Honig PJ, Leyden JJ, McGinley KJ. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics 1982;69:81-3.
133. Givens TG, Murray MM, Baker RC. Comparison of 1% and 2.5% selenium sulfide in the treatment of tinea capitis. Arch Pediatr Adolesc Med 1995;149:808-11.
134. Drug topics red book 1995. Montvale, NJ: Medical Economics Data, 1995.